Regulatory approval

Published by the Health Service Executive. Approved

Treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS >= 1.

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Pembrolizumab - Reimbursement by exception; Paclitaxel, Carboplatin, Bevacizumab - N/A

Citation

Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6425/811_V2_Pembrolizumab_Pac_Carbo_Bev.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2023-04-17	Health Service Executive	Indication approved for reimbursement.